<DOC>
	<DOCNO>NCT01920308</DOCNO>
	<brief_summary>The purpose study assess deliverability , clinical utility effectiveness 5 mm diameter size offering LifeStent® Vascular Stent</brief_summary>
	<brief_title>A Prospective Study Performance Bard® LifeStent® Vascular Stent Systems ( REALITY )</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>The subject legal representative inform nature evaluation , agree provision , sign informed consent form ( ICF ) Subject agree comply protocolmandated followup procedure visit The subject ≥ 21 year old Female subject childbearing potential must negative urine serum pregnancy test within seven day prior index procedure . Female subject surgically sterile postmenopausal exempt pregnancy test The subject moderate lifestylelimiting claudication mild tissue loss define : Rutherford Category1 25 ( moderate claudication minor tissue loss The target lesion ( ) angiographic evidence stenosis restenosis ≥50 % occlusion SFA and/or popliteal artery ( visual estimate ) amenable PTA stenting The target vessel reference diameter ( visual estimate ) appropriate treatment available stent diameter 5.0 mm A total two stent may use cover lesion . Overlapping allow There angiographic evidence least one vessel runoff foot ( level malleolus The subject unable unwilling provide inform consent unable unwilling comply study followup procedure visit The subject claudication critical limb ischemia describe Rutherford Category1 0 ( asymptomatic ) , 1 ( mild claudication ) , 6 ( major tissue loss ) The subject know contraindication ( include allergic reaction ) sensitivity antiplatelet/anticoagulant medication , nickel , titanium tantalum The subject know sensitivity contrast medium amenable pretreatment steroid or/and antihistamines The subject history bleeding diatheses coagulopathy The subject concomitant renal failure creatinine &gt; 2.5 mg/dL The subject concomitant hepatic insufficiency , thrombophlebitis , uremia , systemic lupus erythematosus ( SLE ) , deep vein thrombosis ( DVT ) time study procedure The subject receive dialysis immunosuppressive therapy The subject participate investigational drug another investigational device study The subject another medical condition , , opinion investigator , may cause him/her noncompliant protocol , confound data interpretation , associate limited life expectancy less two year The subject extensive peripheral vascular disease , , opinion investigator , preclude safe insertion introducer sheath The target lesion ( ) locate within aneurysm associate aneurysm vessel segment either proximal distal target lesion ( ) The subject angiographic evidence poor inflow , would deem inadequate support vascular bypass graft The subject diagnose septicemia time study procedure Patients stent previously implant target vessel Lesions require use two stent Bilateral disease native SFA and/or proximal popliteal artery limbs meet inclusion/exclusion criterion plan treat limb within 30 day . Note : One limb may enrol study , second limb plan treat 30 day followup telephone screen take place . The limb may enrol limb severe lesion reason treat specific limb need state CRF</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>